Fluid Management of Acute Heart Failure With the Reprieve System

Read full text
Authors: James E Udelson, A J Ali Javaheri, Marat Fudim, Kevin Damman, Jan Biegus, Aasim M. Afzal, Alpesh Amin, Daniel Bensimhon, Jason J. Bischof, Eugene S Chung, Robert Gottlieb, Simon A. Mahler
+7 more Jonathan D. Moreno, P P Piotr Ponikowski, Veena Rao, Zachary Cox, Juan Ivey-Miranda, Sean Collins, Jeffrey Testani
Cited by: 1
References: 32

Abstract

BACKGROUND: The Reprieve System is designed to overcome barriers limiting safe and rapid decongestion with individualized automated diuretic titration, real-time diuretic response monitoring, and individualized sodium chloride replacement to prevent cardio-renal dysfunction. OBJECTIVES: This study aims to establish proof-of-concept that the Reprieve System can facilitate rapid and safe decongestion. METHODS: FASTR (Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System [DMS]) was a randomized pilot trial comparing the Reprieve System vs a control strategy of optimal diuretic therapy (ODT) in hospitalized patients with acute heart failure. The primary efficacy endpoint was 24-hour natriuresis, and the primary safety endpoint was a composite of dialysis or doubling of creatinine levels, severe electrolyte abnormalities, hypotension, or hypertensive emergency. RESULTS: ) with estimated excess fluid volume of 20 lbs (Q1-Q3: 15-35 lbs). Twenty-four-hour natriuresis was significantly greater with the Reprieve System (1,082 ± 487 mmol) vs ODT (423 ± 290 mmol; P < 0.001). The safety endpoint occurred in 31% of the Reprieve group vs 39% of the ODT group (P = 0.42). Intravenous diuretic therapy duration was shorter with Reprieve [46 hours [Q1-Q3: 29-80 hours]) vs ODT (88 hours [Q1-Q3: 44-143 hours]; P = 0.014). The rate of weight loss (P = 0.002), net fluid loss (P = 0.03), and net natriuresis (P < 0.001) were significantly faster with Reprieve. Change in serum creatinine levels did not differ between the Reprieve (0.19 ± 0.24 mg/dL) and ODT (0.31 ± 0.39 mg/dL; P = 0.07) groups. CONCLUSIONS: In this pilot trial, the Reprieve System safely produced significantly faster decongestion compared with ODT. Confirmation of these findings in the ongoing pivotal trial is required. (Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System [DMS] [FASTR]; NCT05174312).

Fields of Study & Subjects

Electrolyte and hormonal disorders Heart Failure Treatment and Management Acute Kidney Injury Research

Publication details

Journal / source
JACC Heart Failure
Publisher
Elsevier BV
Volume
14
Issue
8
Pages
103062–103062
Publication date
1 May 2026
Language
EN